Context Therapeutics Appoints Andy Pasternak as Chairman of the Board

Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company developing T cell engagers for solid tumors, announced today the appointment of Andy Pasternak as Chairman of its Board of Directors. Pasternak succeeds Richard Berman, who stepped down from the Board effective January 12, 2025, after four years of service. Pasternak brings over 25 years of experience in the biopharmaceutical industry, including leadership roles in corporate strategy, M&A, and commercial development. His vision is to leverage this expertise to keep Context at the forefront of T cell engager innovation and improve outcomes for patients with solid tumors.

Most recently, Pasternak served as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, where he played a central role in the $28 billion acquisition of Horizon by Amgen in 2023. He is currently an advisory partner at Bain & Company, a board member at Endo, Inc., and an adjunct lecturer at Northwestern University’s Kellogg School of Management. Context’s CEO, Martin Lehr, expressed gratitude to outgoing Chairman Richard Berman for his invaluable contributions over the past four years and welcomed Pasternak’s extensive pharmaceutical expertise to guide the company through its next phase of growth.